The headline reads as positive (92% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › UNH
UnitedHealth Group Incorporated (UNH) stock analysis
WEAK BUY 20% confidence · analysed Sep 30, 2026
On Sep 30, 2026, our model rated UnitedHealth Group Incorporated (UNH) WEAK BUY with 20% confidence at a price of $374.94. That means the signals lean positive, but they are mixed, so conviction is low.
SectorHealthcare
IndustryHealthcare Plans
Market cap336.54B
Analysed price$374.94
Technical picture
The 14-day RSI is 33. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is only 0.6x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $458.79 and the swing low is $252.96; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 1.02, which looks reasonably priced for its growth.
The company reports a profit margin of 3.1% and revenue growth of +0.4%.
In its latest quarter it earned $6.38 per share, which beat the $4.92 analysts expected, with revenue +0.4% year over year.
Wall Street's average rating is 1.6 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $481.72.
The next earnings report is expected around Oct 13, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $368.08, a target of $379.90 (+3.2%) and a stop-loss at $352.28 (-4.3%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Oct 10, 2026 whatever the price does.
Entry$368.08
Target$379.90
Stop-loss$352.28
Reassess byOct 10, 2026
Research notes
UnitedHealth’s bull case is still anchored by improving earnings momentum, with Q2 operating earnings up 55% on flat revenue and management pointing to better Medicare Advantage execution and margin recovery; several analysts have also lifted targets, with consensus still broadly positive around a mid-$450s to high-$470s range. The bear case centers on valuation at roughly 19x 2026 earnings, plus ongoing pressure from Medicare Advantage and Optum/medical-cost trends that could keep margins below historical levels. A major recent catalyst was the strong Q2 report and raised full-year EPS guidance to about $19.50–$20.00, which reinforced the recovery narrative. The latest public information and price action do agree with the prior neutral view becoming somewhat more constructive: the stock is still below the prior $374.94 mark by about 6.5%, but fundamentals and analyst sentiment have improved.
The model's one-paragraph read
Leans BUY — composite score +0.20 (WEAK BUY). Technicals: RSI 33.3, MACD bullish, price below SMA50. Fundamentals: PEG 1.02, margin 3.1%, revenue growth 0.4%. Financial results: YoY revenue +0.4%, last EPS surprise +29.7%, next earnings 2026-10-13. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Memory: 1 prior look(s). Internet research: UnitedHealth’s bull case is still anchored by improving earnings momentum, with Q2 operating earnings up 55% on flat revenue and management pointing to better Medicare Advantage execution and margin recovery; several analysts have also lifted targets, with consensus still broadly positive around a mid-$450s to high-$470s range. The bear case centers on valuation at roughly 19x 2026 earnings, plus ongoing pressure from Medicare Advantage and Optum/medical-cost trends that could keep margins below historical levels. A major recent catalyst was the strong Q2 report and raised full-year EPS guidance to about $19.50–$20.00, which reinforced the recovery narrative. The latest public information and price action do agree with the prior neutral view becoming somewhat more constructive: the stock is still below the prior $374.94 mark by about 6.5%, but fundamentals and analyst sentiment have improved. Suggested levels: entry $368.08, target $379.9, stop-loss $352.28, exit by 2026-10-10 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for UNH
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 30, 2026 | WEAK BUY | 20% | $374.94 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on UNH
Oct 13, 2026 · UnitedHealth keeps medical costs under control — and raises its outlook again
Oct 13, 2026 · UnitedHealth reports stronger-than-expected quarterly profit and revenue and raises its 2026 profit forecast
The headline reads as positive (94% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
- Oct 14, 2026: This U.S. healthcare stock is Mizuhos top pick after strong Q3 results (Investing.com)
- Oct 14, 2026: UNH Stock Outpaces S&P 500 In 2026, Eyes Best Year Since Pandemic CFO Says Wall Street May Be Missing 2027 Upside (Stocktwits)
- Oct 13, 2026: UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? (Zacks)
- Oct 13, 2026: UnitedHealth keeps medical costs under control — and raises its outlook again (MarketWatch Top)
- Oct 13, 2026: UnitedHealth reports stronger-than-expected quarterly profit and revenue and raises its 2026 profit forecast (CP24)
- Oct 13, 2026: UnitedHealth reports stronger-than-expected quarterly profit and revenue, raises 2026 profit forecast (Associated Press)
- Oct 13, 2026: UnitedHealth shares are doing something unusual ahead of earnings (CNBC Investing)
- Oct 13, 2026: UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs (CNBC)
Other Healthcare stocks we cover
ZBH · ALC · AMGN · AMRX · ANIP · ASTH · ATEC · ATRC · BCRX · BDX · BIIB · BMY
Frequently asked questions
Is UNH a buy right now?
As of Sep 30, 2026, our automated model rates UnitedHealth Group Incorporated (UNH) WEAK BUY with 20% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for UNH?
The model's most recent plan targets $379.90 with a stop-loss at $352.28, from an entry near $368.08.
When does UnitedHealth Group Incorporated report earnings next?
The next earnings report is expected around Oct 13, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.